Detalles de la búsqueda
1.
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
N Engl J Med
; 388(9): 813-823, 2023 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856617
2.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38246194
3.
TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells.
Nucleic Acids Res
; 51(22): 12224-12241, 2023 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37953292
4.
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
Cancer Immunol Immunother
; 72(3): 697-705, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36045304
5.
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Oncologist
; 23(1): 16-24, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29038234
6.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med
; 372(21): 2006-17, 2015 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25891304
7.
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Invest New Drugs
; 36(6): 1060-1071, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29980894
8.
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Endocr Pract
; 24(3): 243-255, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29547049
9.
Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pharmacol Res
; 123: 95-102, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28690075
10.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 17(11): 1558-1568, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27622997
11.
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining.
Proc Natl Acad Sci U S A
; 108(2): 540-5, 2011 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-21187428
12.
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.
Clin Cancer Res
; 30(1): 74-81, 2024 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37535056
13.
Synthetic lethality: exploiting the addiction of cancer to DNA repair.
Blood
; 117(23): 6074-82, 2011 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-21441464
14.
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
J Immunother Cancer
; 11(8)2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37536936
15.
Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cells.
Invest New Drugs
; 30(1): 114-20, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20820908
16.
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial.
Elife
; 112022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35787784
17.
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Clin Cancer Res
; 28(15): 3248-3255, 2022 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576438
18.
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
Melanoma Res
; 31(4): 378-388, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34193804
19.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
J Immunother Cancer
; 9(6)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117113
20.
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Cancer Med
; 10(13): 4302-4311, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33982452